Description
Pyrroloquinoline quinone, PQQ for short, is a new coenzyme different from nicotinamide nucleotides (NAD + and NADP +) and flavin nucleotides (FAD and FMN). PQQ is a cofactor of dehydrogenase redox reaction in bacteria. In 1979, Durine and other researchers separated the coenzyme from bacteria, and then its structure was confirmed as 4,5-dihydro-4,5-dioxo-1-hydropyrrolo (2,3-f) quinoline-2,7,9-tricarboxylic acid.
PQQ is widely distributed in nature from microorganisms to animal tissues, but it is considered that only Gram-negative bacteria can synthesize PQQ, Human beings can only obtain PQQ through diet to meet the needs of the body system, and the intestinal flora cannot synthesize PQQ. Therefore, exogenous PQQ intake is very important to maintain the needs of human and animal tissues and the stability of intestinal flora.
PQQ has high water solubility and thermal stability. Under neutral or weak alkaline conditions, its carboxyl group can be dehydrogenated into anionic state. Current research shows that the form of PQQ disodium salt is most easily absorbed by human gastrointestinal tract. PQQ has three forms: quinone type (oxidation type), semiquinone type and hydroquinone type (PQQH2), which are transformed into each other through electron and proton transfer. The stable chemical structure and high redox potential make PQQ the bioactive molecule with the strongest ability to catalyze redox reaction so far.
PQQ disodium salt, CAS no.122628-50-6. molecular formula: C14H4N2Na2O8, molecular weight: 374.17.
Efficacy and Mechanism of Action
Antioxidant Mechanism
The production and elimination of various free radicals in organisms should be in dynamic balance. Too many or too few free radicals are unfavorable to the body. Too much will promote the aging of the body and lead to various diseases, including cancer, heart disease and so on. If too little, it will also affect health, even hinder normal metabolism or induce another kind of disease.
In modern society, due to environmental deterioration and irregular diet, the accumulation of free radicals and harmful substances in human body is becoming more and more serious. PQQ, as a redox coenzyme, its special quinone structure can prevent oxidative impairment through the following mechanisms.
1. PQQ can catalyze the mutual conversion of oxygen and O2, so as to help the body maintain free radical balance.
O2+e-+H+⇋[PQQ↔PQQH2]⇋O2-+H+
2. PQQ combines with superoxide dismutase (SOD) to form a broad-spectrum oxidase system that produces hydrogen peroxide, so as to inhibit the damage of superoxide anion free radical to cells. SOD is used as apoenzyme protein and PQQ is used as non-covalently bound redox auxiliary group.
2O2+2e- →2O2-
2O2+NAD++H+(PQQ coenzyme) →NADH+2O2
3. By accelerating the reaction of "NAD + → NADH", PQQ can convert the utilized oxidized glutathione (GSSG) to reduced glutathione (GSH) faster.
NAD++H+GSSG(GSSG reductase)→2GSH+NAD+
Protect the Heart from Oxidative Impairment
PQQ can eliminate reactive oxygen species (ROS) produced by hypoxia reperfusion and significantly reduce the release of lactate dehydrogenase in the heart. Under the catalysis of flavin mononucleotide reductase, its catalytic product can also reduce the peroxidation state of hemoglobin and eliminate the impairment of myocardial ischemia reperfusion.
Studies have shown that PQQ can protect the heart of ischemia-reperfusion mice, significantly reduce the scope of myocardial infarction, enhance the rise and fallen rate of left ventricular pressure and left ventricular diastolic pressure, reduce ventricular fibrillation and reduce the level of malondialdehyde in myocardial tissue.
PQQ can also inhibit the production of ROS in rat cardiomyocytes induced by hydrogen peroxide and the decrease of mitochondrial membrane potential, so as to reduce oxidative stress, inhibit the inactivation of mitochondrial function and protect rat cardiomyocytes.
Prevention of Hepatic Impairment
The liver is the main metabolic and detoxifying organ of animals and human body. In the research, researchers found that the experimental Hepatic Impairment of rats caused by carbon tetrachloride (CCl4), galactosamine, thioacetamide and other toxins can be prevented by injecting a certain dose of PQQ and its derivatives into the abdominal cavity in advance.
PQQ can reduce the production of ROS caused by liver toxic substances, significantly reduce the levels of serum bilirubin, glutamic pyruvic transaminase (GPT) and lactate dehydrogenase, prevent hepatic cell necrosis, and do not affect the routine biochemical indexes of rats (such as blood glucose, hematuria nitrogen, etc.).
Promote Nerve Growth and Protect the Nervous System
Nerve growth factor (NGF) is the earliest and most thoroughly studied neurotrophic factor. It has the dual biological functions of neuronal nutrition and neuroprotection. It plays an important regulatory role in the growth, development, differentiation, regeneration and biological function specific expression of central and peripheral neurons. The study results showed that PQQ could stimulate L-M cells and Schwann cells to produce NGF in vitro.
Prevent Acetaldehyde Poisoning
Acetaldehyde is the intermediate metabolite of alcohol in animals, which is toxic. Many people have acetaldehyde dehydrogenase gene mutation and incomplete function, lead to acetaldehyde accumulation after drinking, resulting in slight acetaldehyde poisoning reactions such as blushing and dizziness.
Studies in rodents have found that PQQ contributes to the metabolism of acetaldehyde. PQQ (11.5mg/kg body weight) was injected intraperitoneally before ethanol was injected into the stomach. It was found that there was no significant difference in ethanol concentration in blood and liver between the treatment group and the control group, but the acetaldehyde concentration of the former was much lower than that of the latter. Replacing PQQ with other quinone derivatives such as coenzyme Q10 has a similar effect.
Regulatory Dosage and Usage
The safety Study in Animal
The Safety Study of Oral Dose PQQ in Rats
| Gender | Oral Duration/Day | Oral Dose in Rats (Mg/Kg/Day) | Adverse Reactio | ||
| Male | 14 | Half lethal dose (LD50) | 1000-2000 | Nil | |
Female | 14 | 500-1000 | Reversible adverse reaction | Increased kidney weight | |
Increased urinary protein and crystallinit | |||||
Male | 91 | 400 | Nil | ||
Female | 91 | 400 | Nil | ||
In the human controlled double-blind clinical trial, volunteers treated with PQQ 60mg / day for one month, and there were no adverse reactions and no changes in renal injury markers. The safe dosage of FDA is: healthy adults about 60kg treated with a dose of 240mg PQQ every day, and there are few adverse events.
USFDA recommended the use scope and maximum use level of PQQ
Table 4-1 Summary of the Individual Proposed Food-Uses and Use-Levels for PQQ disodium salt in the U.S.(2011-2012 NHANES Data)
| Food Category | Food-Uses | PQQ Level(mg/serving) | RACC*(g or mL) | Use-Levels(%) |
| Beverages and Beverage Bases | Energy, Sport and lsotonic Drinks | 20 | 240 | 0.008 |
| Non-Milk Based Meal Replacement Beverages | 20 | 240 | 0.008 | |
| Water(Bottled, Enhanced, Fortified) | 20 | 240 | 0.008 | |
| Milk Products | Milk-Based Meal Replacement, and Fortified Bars | 20 | 240 | 0.008 |
Grain Products and Pastas | Cereal and Granola Bars | 20 | 40 | 0.05 |
| Energy, Meal Replacement, and Fortified Bras | 20 | 40 | 0.05 |
*RACC=Reference Amounts Customarily Consumed per Eating Occasion(21 CER 101.12 - CFR,2014b). When a range of values is reported for a proposed food-use, particular foods within that food-use may differ with respect to their RACC.
USFDA proposed daily intake of PQQ by population group
Table 4-2 Summary of the Estimated Daily Intake of PQQ Disodium Salt from Proposed Food-Uses in the U.S. by Population Group(2011-2012 NHANES Data)
| Population Group | Age Group (Yeasr) | All-Person Consumption(mg/day) | All-User Consumption(mg/day) | ||||
| Mean | 90th Percentile | % Users | n | Mean | 90th Percentile | ||
| Infants | 0 to 2 | 7.8 | 27.3 | 38.3 | 271 | 20.3 | 42.7 |
| Children | 3 to 11 | 16.4 | 46.4 | 58.6 | 943 | 28.0 | 60.3 |
| Female Teenagers | 12 to 19 | 34.4 | 90.4 | 68.7 | 354 | 50.1 | 105.0 |
| Male Teenagers | 12 to 19 | 37.2 | 108.0 | 63.1 | 328 | 58.9 | 145.0 |
| Female Adults | 20 to up | 35.9 | 109.0 | 55.7 | 1296 | 64.5 | 149.0 |
| Male Adults | 20 to up | 39.1 | 132.0 | 51.8 | 1165 | 75.4 | 168.0 |
| Total Population | All Ages | 33.6 | 100.0 | 55.2 | 4357 | 60.9 | 145.0 |
Table 4-3 Summary of the Estimated Daily Per Kilogram Body Weight Intake os PQQ Disodium Salt from Proposed Food-Uses in the U.S. by Population Group(2011-2012 NHANES Data)
| Population Group | Age Group (Yeasr) | All-Person Consumption(mg/day) | All-User Consumption(mg/day) | ||||
| Mean | 90th Percentile | % | n | Mean | 90th Percentile | ||
| Infants | 0 to 2 | 0.63 | 2.11 | 38.3 | 270 | 1.63 | 3.52 |
| Children | 3 to 11 | 0.60 | 1.68 | 58.6 | 943 | 1.03 | 2.36 |
| Female Teenagers | 12 to 19 | 0.58 | 1.49 | 68.9 | 346 | 0.84 | 1.79 |
| Male Teenagers | 12 to 19 | 0.54 | 1.55 | 63.1 | 327 | 0.85 | 1.85 |
| Female Adults | 20 to up | 0.49 | 1.49 | 55.6 | 1281 | 0.88 | 1.93 |
| Male Adults | 20 to up | 0.46 | 1.46 | 51.6 | 1153 | 0.88 | 2.06 |
| Total Population | All Ages | 0.50 | 1.53 | 55.1 | 4320 | 0.91 | 2.07 |
Product Specification
Production and Quality Control
Angel yeast Co., Ltd. was founded in 1986, specializing in the processing and manufacturing of yeast and yeast derivatives. Its production and marketing scale ranks first in Asia and third in the world. It has established a global marketing network, regional headquarters and application technology service centers in Beijing, Shanghai, Chengdu, Shenyang, Wuhan, Guangzhou, Cairo and other cities, and products are exported to more than 150 countries and regions.
Angel yeast Co., Ltd. has passed ISO9001 quality management system certification, HACCP certification, GMP certification and kosher certification, and the testing center has been recognized by CNAs, providing a reliable guarantee for the production of products.
MaiggicTM vitamin K2 (MK-7) is produced by Angel yeast Co., Ltd., entrusted by Hubei Magic Health Technology Co., Ltd. Hubei Magic Health Technology Co., Ltd. has a series of internationally leading production and application technologies.
Package Specification
Inner: Aluminum Foil bag, Outer: various specifications with Carton or paper bucket.
Formulations | Material Code | Packaging Size |
1kg×10 bags/Carton | ||
5kg×2 bags/Carton |
Shelf life
Store in cool, dry and airy place, with a shelf life of 24 months.